Antineoplaston Therapy in Treating Adults With Residual/Recurrent/Progressive Glioblastoma Multiforme
Status:
Completed
Trial end date:
2003-06-21
Target enrollment:
Participant gender:
Summary
RATIONALE: Current therapies for Glioblastoma Multiforme provide very limited benefit to the
patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove
beneficial in the treatment of brain tumors.
PURPOSE: This study is being performed to determine the effects (good and bad) that
Antineoplaston therapy has on adults (≥ 18 years of age) with residual/recurrent/progressive
Glioblastoma Multiforme.